Hemab Therapeutics
Created in 2019
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
3,829Activities
Technologies
Entity types
Location
Ole Maaløes Vej 3, 2200 København, Denmark
København
Denmark
Employees
Scale: 11-50
Estimated: 45
Engaged corporates
1
0 1Added in Motherbase
1 year, 3 months ago
deeptech Value proposition
The next generation of therapeutics for bleeding and thrombotic disorders
Hemab is a clinical-stage biotech company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. Based in Cambridge, Massachusetts and Copenhagen, Denmark, Hemab is progressing a pipeline of monoclonal and bispecific antibody-based therapeutics to transform the treatment paradigm for patients with high unmet need. The company’s strategic guidance, Hemab 1-2-5, targets the development of 5 clinical assets by 2025 to deliver long-awaited innovation for patients with high unmet need blood clotting disorders like Glanzmann Thrombasthenia, factor VII deficiency, Bernard Soulier Syndrome, Von Willebrand Disease and other serious disorders. Learn more at hemab.com.
Biotech
Hemab - bleeding disorder company
Hemab is pioneering the first preventative treatments and functional cures for patients with rare bleeding and thrombotic disorders.
https://hemab.com/
